Plate Nº 37 · recorded November 16, 2026

Health & Medicine ResearchReported finding

MAR001 injection cut triglycerides by up to 45% in trial

A 24-week trial found that three doses of MAR001 lowered fasting triglycerides by 39% to 45% versus placebo, but the drug has not yet shown fewer heart attacks or pancreatitis.

By Elena Vasquez3 min read593 words

In brief

  1. The phase 2b trial enrolled 236 adults; 235 received at least one injection and entered the main analysis.
  2. Three MAR001 doses lowered fasting triglycerides by about 39% to 45% compared with placebo.
  3. Dosing occurred every four weeks for 24 weeks at 48 centres in four countries.
  4. Side effects were not reported more often with MAR001 than with placebo.
  5. The findings were published November 9, 2026, in The New England Journal of Medicine and presented at the American Heart Association’s annual scientific meeting.
New injection cuts high blood fats by up to 45% in trial
Plate Nº 37New injection cuts high blood fats by up to 45% in trial — Belova59 / pixabay

By Elena Vasquez

Three doses of the experimental injection MAR001 lowered fasting triglyceride levels by about 39% to 45% compared with placebo in a 24-week phase 2b clinical trial led by Mass General Brigham researchers.

The result supports further testing of MAR001 for people with unusually high triglycerides. It does not show that the injection prevents heart attacks or pancreatitis.

What did the trial find?

The study enrolled 236 adults with unusually high levels of triglycerides, a type of fat in the blood that helps the body store energy from food. When triglycerides become too high, they can contribute to heart and blood-vessel problems. Extremely high levels can cause inflammation of the pancreas, known as pancreatitis, which may be painful and potentially dangerous.

The phase 2b trial tested three dose levels and their side effects rather than whether patients had fewer heart attacks or cases of pancreatitis. Its main design was straightforward:

  • Researchers randomly assigned participants to one of three MAR001 doses or a placebo, an injection without the active drug.
  • Dosing occurred every four weeks for 24 weeks.
  • The trial ran at 48 centres in the United States, Canada, Australia and New Zealand.
  • Researchers included 235 participants who received at least one injection in the main analysis out of 236 enrolled adults.
  • The main comparison focused on changes in triglycerides after the first 12 weeks.

In that comparison, all three doses lowered fasting triglycerides by roughly 39% to 45% compared with placebo. Researchers said the difference was meaningful, suggesting that MAR001 was doing more than changes that might have happened without the drug.

Side effects were not reported more often among people receiving MAR001 than among those receiving placebo.

Takeaway: All three doses produced large reductions, and people taking MAR001 did not report side effects more often than those taking placebo.

How does MAR001 work?

MAR001 works differently from commonly prescribed medicines. It blocks ANGPTL4, a protein that normally slows an enzyme that clears triglycerides from the bloodstream. By blocking that protein, the injection aims to help the body remove more of these fats from the blood.

Scientists have been interested in this approach because some people naturally have changes in the relevant gene that are linked to healthier blood-fat levels.

Takeaway: MAR001 blocks one protein that slows triglyceride clearance, with the aim of helping the body remove more fat from the blood.

Could MAR001 prevent serious complications?

Researchers say the treatment could eventually offer another option for people whose blood fats remain high despite existing care. The findings offer encouraging evidence that blocking ANGPTL4 can lower triglycerides, particularly for patients who need better control.

The trial does not show that lower readings mean fewer heart attacks or cases of pancreatitis. Researchers need larger and longer trials to determine whether MAR001 prevents those outcomes.

The trial’s size and 24-week duration also limit the safety conclusions. Although side effects were no more frequent with MAR001 than with placebo, the study cannot rule out uncommon problems or risks that emerge only after longer treatment.

Takeaway: MAR001 may help control blood fats, but the trial cannot show whether it prevents heart attacks or pancreatitis.

When were the results published, and who funded the trial?

The New England Journal of Medicine published the findings on November 9, 2026, and the team presented them at the American Heart Association’s annual scientific meeting. Marea Therapeutics, the drug’s developer, funded the study.

Takeaway: These are encouraging results from one phase 2b trial, not proof that MAR001 prevents disease over the long term.

via knowridge.com (Source)

Filed under

  • mar001
  • triglycerides
  • angptl4
  • hypertriglyceridemia
  • phase-2b-clinical-trial
Share this article:

More from Elena Vasquez

Elena Vasquez

Show full bio

Correspondent covering money, funding and market shifts around general science news at SciBeat.

451 articles

Nearby plates

« Previous articleNext article »